Matthew K. Fust - Sep 14, 2023 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Matthew K. Fust
Stock symbol
NMRA
Transactions as of
Sep 14, 2023
Transactions value $
$0
Form type
4
Date filed
9/18/2023, 05:51 PM
Previous filing
Jun 21, 2023
Next filing
Mar 11, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Award $0 +27.8K $0.00 27.8K Sep 14, 2023 Common Stock 27.8K $17.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 100% of the shares subject to the option shall vest and become exercisable on the date of the 2024 Annual Meeting, subject to the Reporting Person continuing in service on the Board through such vesting date.